BMY dough (@tgtxdough) 4/18/18, 7:42 AM BMO $BMY key growth driver Opdivo will face significant headwinds in 2019 as the 2L-NSCLC market shrinks with Keytruda's 1L uptake doubt CM-227 will produce superior data in 2H18/1H19; CM-9LA has a good chance, but that's expected 2H19. PT 47
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.